AbCellera Biologics (ABCL) saw its stock price plummet 5.01% in Thursday's trading session, as investors appear to be positioning themselves ahead of the company's upcoming third-quarter earnings report. The biotechnology company, known for its AI-powered antibody discovery platform, is scheduled to release its financial results after market close on Thursday.

According to the earnings calendar, analysts expect AbCellera to report a loss of $0.14 per share for the quarter. The anticipation of these results seems to have triggered a sell-off, with some investors potentially concerned about the company's financial performance or future outlook.

The biotech sector has been facing challenges in recent months, with many companies experiencing volatility due to market conditions and individual company performances. AbCellera's significant drop may reflect broader sector trends as well as company-specific factors.

Investors will be closely watching AbCellera's earnings report for insights into its revenue growth, progress on its antibody discovery programs, and any updates on partnerships or pipeline developments. The company's performance relative to analyst expectations could have a significant impact on its stock price in the coming days.